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Hyperuricaemia is an undisputed and highly predictive biomarker for cardiovascular risk. SLC17A1, 
expressed in the liver and kidneys, harbours potent candidate single nucleotide polymorphisms that 
decrease uric acid levels. Therefore, we examined SLC17A1 polymorphisms (rs1165196, rs1179086, and 
rs3757131), which might suppress cardiovascular risk factors and that are involved in liver functioning, 
via a large-scale pooled analysis of the Japanese general population in a cross-sectional study. Using 
data from the Japan Multi-Institutional Collaborative Cohort Study, we identified 1842 participants 
of both sexes, 35–69-years-old, having the requisite data, and analysed their SLC17A1 genotypes. In 
men, logistic regression analyses revealed that minor alleles in SLC17A1 polymorphisms (rs1165196 and 
rs3757131) were associated with a low-/high-density lipoprotein cholesterol ratio >2.0 (rs1165196: odds 
ratio [OR], 0.703; 95% confidence interval [CI], 0.536–0.922; rs3757131: OR, 0.658; 95% CI, 0.500–0.866), 
and with homocysteine levels of >10.0 nmol/mL (rs1165196: OR, 0.544; 95% CI, 0.374–0.792; rs3757131: 
OR, 0.509; 95% CI, 0.347–0.746). Therefore, these polymorphisms had dominant negative effects on 
cholesterol homeostasis and hyperhomocysteinaemia, in men, independent of alcohol consumption, 
physical activity, or daily energy and nutrition intake. Thus, genetic variants of SLC17A1 are potential 
biomarkers for altered cholesterol homeostasis and hyperhomocysteinaemia in Japanese men.
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Cardiovascular diseases, including coronary heart disease, stroke, and peripheral arterial disease, are the 
most prevalent conditions and leading causes of mortality, worldwide. In addition, age, sex, overweight, 
hypertension, smoking, and diabetes are widely accepted as major risk factors for the development of 
cardiovascular disease1. Furthermore, recent studies have reported that hyperuricaemia2–4 and elevated 
levels of homocysteine5,6 are also associated with cardiovascular disease, and a significant positive corre-
lation has been observed between the serum concentrations of uric acid and homocysteine7.
In addition to the above-mentioned factors, altered lipid metabolism, such as the disruption of cho-
lesterol homeostasis via altered liver function, is another major risk factor for cardiovascular disease8. 
Cholesterol is a critical lipid that is a component of biological cell membranes and is an important precur-
sor of steroid hormones and bile acids. Unfortunately, the disruption of cholesterol homeostasis signifi-
cantly increases the risk of premature cardiovascular disease9. To monitor for this disruption, low-density 
lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) are among the most 
commonly used clinical biomarkers10, with high LDL-C and low HDL-C levels indicating major risks for 
the development of coronary heart disease11. In addition, prospective studies investigating different racial 
and ethnic populations have confirmed that HDL-C is a strong, consistent, and independent predictive 
factor for the incidence of cardiovascular disease10,12. Furthermore, the Framingham study demonstrated 
that a combination of high LDL-C and low HDL-C levels is a strong predictor of the relative risk of car-
diovascular events13. Moreover, the LDL-C/HDL-C ratio is a precise marker of cholesterol homeostasis, 
and can help predict cardiovascular events14.
Previous genome-wide association studies have examined the genetic factors that control serum uric 
acid concentrations, and have identified 14 candidate causal single nucleotide polymorphisms (SNPs) 
and two pathways involving the PKD2, SLC17A1, SLC17A3, SLC17A4, and SLC2A9 genes15. One of 
these genes (SLC17A1) encodes the solute carrier family 17 (organic anion transporter), member 1, 
which is also known as sodium phosphate transport protein 1. This protein is expressed in the sinusoidal 
membrane of hepatocytes and in the proximal tubules in the kidneys16; in the proximal tubules, it acts 
as a renal transporter of uric acid and mediates the co-transport of sodium and inorganic phosphate17. 
Additionally, SLC17A1 SNPs are associated with kidney function indicators, such as suppressed serum 
uric levels and gout, in Japanese men18. Because hyperuricaemia is an undisputed and highly effective 
biomarker for predicting cardiovascular risk, SLC17A1 SNPs might also suppress cardiovascular risk 
factors. However, whether SLC17A1 SNPs, associated with liver function, are also associated with car-
diovascular risk factors remains unknown. Cholesterol and homocysteine are both metabolised in the 
liver; therefore, we analysed three SLC17A1 SNPs (rs1165196, rs1179086, and rs3757131) to evaluate 
their association with cholesterol homeostasis and homocysteine levels, and their roles as predictors of 
cardiovascular events. This analysis was conducted as a cross-sectional study using a large-scale pooled 
analysis of the Japanese general population.
Results
Participant characteristics. Table 1 shows the participants’ characteristics, including their anthropo-
metric measures, blood chemistry data, questionnaire responses, total energy and macronutrient intake, 
and distribution of the three polymorphisms according to sex. The mean age of the included men was 
55.6 years, compared to 54.8 years for the women. Significant differences were not observed in compar-
isons of the metabolic equivalents (METs) and polymorphism allele frequency data between the men 
and women. Furthermore, the allele frequencies for the polymorphisms were similar to those in other 
Japanese populations18, and were in agreement with the Hardy-Weinberg equilibrium (rs1165196 for 
men: χ 2 = 0.571, p = 0.319; rs1165196 for women: χ 2 = 1.241, p = 0.265; rs1179086 for men: χ 2 = 0.023, 
p = 0.877; rs1179086 for women: χ 2 = 1.350, p = 0.245; rs3757131 for men: χ 2 = 0.284, p = 0.593; 
rs3757131 for women: χ 2 = 1.053, p = 0.304).
Associations between polymorphisms and participant characteristics, according to sex. The 
distributions of the three polymorphism genotypes are listed in Tables 2–4. For each genotype, the major 
homozygotes had significantly higher levels of uric acid, compared to the heterozygotes and minor 
homozygotes, in both sexes. Similarly, the major homozygous alleles in rs1165196 and rs3757131 exhib-
ited high homocysteine and low folic acid levels in men. We also compared the major homozygotes with 
the heterozygotes and minor homozygotes. In men, rs1165196 and rs3757131 exhibited similar statistical 
significance. When compared to the major homozygous alleles, the combined minor genotype (TC + CC 
in rs1165196 and CT + TT in rs3757131) was associated with significantly higher folic acid levels, and 
significantly lower uric acid and homocysteine levels. In contrast, women did not demonstrate any sig-
nificant variables associated with uric acid and homocysteine levels in each genotype.
Associations of polymorphism genotypes with LDL-C/HDL-C ratios and homocysteine levels. 
Table 5 shows the proportion of participants with LDL-C/HDL-C ratios ≤ 2.0 and those > 2.0, according 
to the polymorphism genotypes. For the logistic regression analysis, the major homozygous genotypes 
were used as the reference group and the heterozygous and minor homozygous genotypes were used as 
the exposed group in the dominant model. When we combined the TC and CC genotypes for rs1165196 
as the low-risk genotype comparison group (assuming a dominant effect for the variant C allele), the 
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combined genotype (TC + CC) in men was associated with a significantly lower proportion of partici-
pants with an LDL-C/HDL-C ratio of > 2.0 (OR, 0.703; 95% CI, 0.536–0.922; OR adjusted for age, body 
mass index [BMI], research area, alcohol consumption and smoking habits, 0.642; 95% CI, 0.483–0.853), 
relative to the TT genotype. The combined genotype (CT + TT) in rs3757131 was also associated with 
a significantly lower proportion of participants with an LDL-C/HDL-C ratio > 2.0 (OR, 0.658; 95% CI, 
0.500–0.866; OR adjusted for age, BMI, research area, alcohol consumption and smoking habits, 0.607; 
95% CI, 0.455–0.808), relative to the major homozygous alleles. When we compared the rs1165196 and 
rs3757131 alleles in men using an LDL-C/HDL-C ratio of > 2.0, rs1165196 had a significantly lower 
Men (n = 995) Women (n = 847)
Mean ± SD (%) CV (%) Mean ± SD (%) CV (%) p-value
Age (years) 55.6 ± 8.8 15.8 54.8 ± 8.5 15.5 0.052
BMI (kg/m2) 23.8 ± 3.1 13.0 22.9 ± 3.3 14.4 < 0.001
Triglycerides (mg/dL) 120.7 ± 61.0 50.5 92.2 ± 49.3 53.4 < 0.001
Total cholesterol (mg/dL) 204.3 ± 31.4 15.3 216.9 ± 35.4 16.3 < 0.001
LDL-C (mg/dL) 120.6 ± 29.7 24.6 129.5 ± 33.7 26.0 < 0.001
HDL-C (mg/dL) 59.5 ± 15.7 26.3 68.9 ± 15.2 22.0 < 0.001
LDL-C/HDL-C 2.17 ± 0.78 35.9 2.00 ± 0.77 38.5 < 0.001
Uric acid (mg/dL) 6.03 ± 1.17 19.4 4.43 ± 0.99 22.3 < 0.001
Folic acid (ng/mL)* 8.61 ± 2.25 26.1 9.75 ± 3.26 33.4 < 0.001
Homocysteine (nmol/mL)** 9.37 ± 3.48 37.1 7.36 ± 2.51 34.1 < 0.001
Energy intake (kcal/day) 1,930 ± 360 18.6 1,547 ± 251 16.2 < 0.001
Protein intake (g/day) 55.8 ± 11.2 20.0 51.3 ± 10.5 20.4 < 0.001
Fat intake (g/day) 41.8 ± 10.5 25.1 44.6 ± 11.7 26.2 < 0.001
Carbohydrate intake (g/day) 278.6 ± 70.3 25.2 216.4 ± 45.1 20.8 < 0.001
METs (h/day) 14.7 ± 14.0 95.2 15.0 ± 13.7 91.3 0.693
Alcohol drinking
 0 g/d 393 (39.4) 593 (70.0)
 0.1–22.9 g/d 414 (41.6) 238 (28.0)
< 0.001 23.0–45.9 g/d 122 (12.2) 15 (1.77)
 ≥ 46.0 g/d 66 (6.63) 1 (0.11)
Smoking
 Current 272 (27.3) 45 (5.31)
< 0.001 Former 433 (43.5) 25 (2.95)
 Never 290 (29.1) 777 (91.7)
rs1165196
 TT 694 (69.7) 612 (72.2)
0.496 TC 271 (27.2) 211 (24.9)
 CC 30 (3.01) 24 (2.83)
rs1179086
 AA 542 (54.4) 467 (55.1)
0.634 AT 386 (38.7) 315 (37.1)
 TT 67 (6.73) 65 (7.67)
rs3757131
 CC 703 (70.6) 610 (72.0)
0.795 CT 264 (26.5) 213 (25.1)
 TT 28 (2.81) 24 (2.83)
Table 1.  Clinical characteristics and genotype frequencies of the participants, according to sex. Data 
are means ± standard deviation. CV, coefficient of variance BMI, body mass index; LDL-C, low-density 
lipoprotein cholesterol. HDL-C, high-density lipoprotein cholesterol; METs, metabolic equivalents. Sex-
related differences were analysed using the t-test, Chi-square tests were used for smoking and alcohol habits 
and genotypes. *Men = 751, Women = 620, **Men = 719, Women = 606.
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frequency of the C allele, whereas rs3757131 had a significantly lower frequency of the T allele (T vs. C 
alleles in rs1165196: OR, 0.726; 95% CI, 0.573–0.920; C vs. T alleles in rs3757131: OR, 0.689; 95% CI, 
0.542–0.876). Furthermore, we found that physical activity and daily energy or nutritional intake did 
not affect the LDL-C/HDL-C ratio in rs1165196 or rs3757131. In contrast, the proportions of women 
with an LDL-C/HDL-C ratio of > 2.0 were not significantly different when the various polymorphism 
genotypes were compared.
Similar analyses were performed for homocysteine levels (Table 6). In men, when we compared the 
alleles for rs1165196 and rs3757131 using homocysteine levels of > 10.0 nmol/mL, rs1165196 had a sig-
nificantly lower frequency of the C allele, whereas rs3757131 had a significantly lower frequency of 
the T allele (T vs. C alleles in rs1165196: OR, 0.589; 95% CI, 0.420–0.826; C vs. T alleles in rs3757131: 
OR, 0.564; 95% CI, 0.399–0.797). Moreover, we confirmed that the tendency attenuated the relationship 
between hyperhomocysteinaemia and the SLC17A1 polymorphisms, after adjusting for folic acid levels. 
In contrast, the proportion of women with homocysteine levels >10.0 nmol/mL were not significantly 
different when we compared the various polymorphism genotypes.
Discussion
High levels of uric acid are historically associated with gout, although recent studies have revealed that 
they might also be associated with cardiovascular disease and the incidence of coronary heart disease, 
hypertension, stroke, metabolic syndrome, and other disorders. Therefore, patients presenting with high 
uric acid levels should be screened and treated for comorbid cardiovascular risk factors19. Furthermore, 
a previous genome-wide association study of uric acid transporters revealed that several SNPs were 
significant genetic determinants of uric acid levels20. In that study, the SLC17A1 polymorphisms exhib-
ited an association with low serum levels of uric acid. The polymorphisms of interest for SLC17A1 are 
rs1165196, rs1179086, and rs3757131; these polymorphisms are known to be associated with low levels of 
uric acid in Japanese men18. However, because these three SNPs exhibit strong linkage disequilibrium18, 
determining which SNP is responsible for the functional changes in SLC17A1 is difficult. In agreement 
with these previous studies, our findings revealed significant associations between the SLC17A1 poly-
morphisms and uric acid levels in Japanese men. Furthermore, in the present study, we also compared 
the associations between various SLC17A1 genotypes and cardiovascular risk factors via altered choles-
terol homeostasis and hyperhomocysteinaemia, after combining the heterozygous and minor homozy-
gous alleles due to the small number of minor homozygotes. Our results indicated that, among male 
participants, the presence of minor alleles in rs1165196 and rs3757131 were associated with significantly 
lower homocysteine levels, compared to the major alleles. In addition, the odds of having a high LDL-C/
Sex Men Women
Genotype (N) TT (694) TC (271) CC (30) p* TC + CC
p** (vs. 




Age (years) 55.5 ± 8.8 55.5 ± 8.9 58.2 ± 7.9 0.271 55.7 ± 8.8 0.730 54.7 ± 8.7 54.8 ± 8.1 58.2 ± 7.0 0.131 55.1 ± 8.1 0.491
BMI (kg/m2) 23.7 ± 3.0 24.1 ± 3.1 23.7 ± 2.9 0.145 24.1 ± 3.1 0.062 22.9 ± 3.3 22.7 ± 3.2 23.5 ± 4.1 0.483 22.8 ± 3.3 0.570
Triglycerides (mg/dL) 120.6 ± 59.4 121.8 ± 64.9 112.8 ± 64.2 0.741 120.9 ± 64.8 0.946 93.4 ± 50.0 88.3 ± 45.8 94.0 ± 59.5 0.433 88.9 ± 47.3 0.238
Total cholesterol (mg/dL) 204.2 ± 31.4 204.0 ± 31.5 211.0 ± 32.1 0.503 204.7 ± 31.6 0.818 217.7 ± 35.1 214.0 ± 36.9 222.0 ± 27.1 0.324 214.8 ± 36.0 0.287
LDL-C (mg/dL) 121.1 ± 29.9 119.3 ± 29.2 121.5 ± 30.0 0.690 119.5 ± 29.2 0.441 129.8 ± 33.1 128.1 ± 36.0 133.8 ± 27.1 0.668 128.7 ± 35.2 0.665
HDL-C (mg/dL) 58.9 ± 15.5 60.3 ± 16.0 66.8 ± 14.3 0.017 60.9 ± 16.0 0.062 69.1 ± 15.4 68.1 ± 15.0 69.4 ± 11.4 0.705 68.3 ± 14.6 0.454
LDL-C/HDL-C 2.20 ± 0.79 2.12 ± 0.75 1.92 ± 0.71 0.069 2.10 ± 0.75 0.053 2.00 ± 0.77 2.00 ± 0.81 1.99 ± 0.58 0.999 2.00 ± 0.79 0.977
Uric acid (mg/dL) 6.10 ± 1.14 5.87 ± 1.21 5.94 ± 1.40 0.020 5.88 ± 1.23 0.005 4.49 ± 1.00 4.27 ± 0.92 4.28 ± 1.22 0.016 4.27 ± 0.95 0.004
Folic acid (ng/mL)* 8.42 ± 2.13 8.98 ± 2.51 9.69 ± 1.80 0.001 9.04 ± 2.46 0.001 9.71 ± 3.08 9.84 ± 3.74 9.84 ± 2.97 0.912 9.84 ± 3.66 0.667
Homocysteine (nmol/mL)** 9.66 ± 3.85 8.70 ± 2.34 8.51 ± 1.53 0.003 8.69 ± 2.29 < 0.001 7.36 ± 2.72 7.38 ± 1.92 7.20 ± 1.92 0.957 7.36 ± 1.91 0.982
Energy intake (kcal/day) 1,929 ± 356 1,933 ± 376 1,919 ± 284 0.976 1,931 ± 367 0.925 1,546 ± 248 1,552 ± 257 1,542 ± 267 0.957 1,551 ± 258 0.813
Protein intake (g/day) 56.0 ± 11.4 55.2 ± 11.0 55.1 ± 9.52 0.587 55.2 ± 10.9 0.303 51.4 ± 10.6 51.4 ± 10.3 50.2 ± 12.3 0.866 51.3 ± 10.5 0.893
Fat intake (g/day) 41.9 ± 10.8 41.4 ± 9.89 43.1 ± 8.78 0.654 41.6 ± 9.78 0.676 44.5 ± 11.7 45.0 ± 11.7 45.1 ± 11.8 0.830 45.0 ± 11.7 0.542
Carbohydrate intake (g/day) 279.0 ± 71.1 278.8 ± 69.8 267.8 ± 56.8 0.695 277.7 ± 68.6 0.797 215.9 ± 43.9 218.6 ± 47.4 211.1 ± 56.6 0.630 217.9 ± 48.3 0.565
METs (h/day) 14.9 ± 14.1 14.4 ± 14.5 13.7 ± 8.7 0.847 14.4 ± 14.0 0.606 15.0 ± 13.5 15.2 ± 14.3 13.2 ± 11.4 0.790 15.0 ± 14.1 0.976
Table 2.  The distribution of the participants, according to sex, for rs1165196. Data are presented as 
means ± standard deviation; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C,  
high-density lipoprotein cholesterol; METs, metabolic equivalents. Genotype differences were analysed 
using one-way analysis of variance*, or the t-test**. *Men (TT = 524, TC = 208, CC = 19) Women (TT= 439, 
TC = 161, CC = 20). **Men (TT = 502, TC = 201, CC = 16) Women (TT = 431, TC = 156, CC = 19).
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HDL-C ratio or hyperhomocysteinaemia were significantly lower for patients with the minor alleles (vs. 
the major homozygous alleles), both before and after adjusting for age, BMI, research area, daily energy 
and nutritional intake, and alcohol consumption and smoking habits.
In healthy humans, uric acid is excreted in the urine, although kidney disease can impair this excre-
tion route, leading to hyperuricaemia. In addition, hyperuricaemia can be caused by the increased gen-
eration of uric acid. Furthermore, exposure to lead or diets involving excessive intake of alcohol, purine 
nucleotides, protein, and carbohydrates can also contribute to high levels of uric acid3. However, in 
the present study, we found that alcohol consumption, physical activity, and daily energy or nutritional 
intake were not different for each SNP. Another potential mechanism leading to high uric acid levels is 
mutation(s) in the genes coding for the glucokinase regulatory protein; PDZ domain-containing pro-
teins; and transporters of organic anions, glucose, ATP-binding cassettes, or monocarboxylic acid15,20,21; 
these transport proteins are key regulators of uric acid levels. Interestingly, SLC17A1 is the gene involved 
in the renal transport of uric acid, and has been associated with low uric acid levels18.
HDL-C is an undisputed and highly predictive biomarker of cardiovascular risk. In this context, 
HDL-C is central to reverse cholesterol transport, which is the cardioprotective mechanism by which 
cholesterol, synthesized in the peripheral tissues, is transported to the liver for degradation or recycling. 
Various factors can result in elevated HDL-C levels, including smoking, alcohol consumption, exercise, 
and statin therapy. However, epidemiological studies have demonstrated that uric acid levels are inversely 
correlated with HDL-C levels22, and that there is a strong relationship between LDL-C levels and the 
incidence of atherosclerotic cardiovascular disease10,23. Another recent study has demonstrated that the 
LDL-C/HDL-C ratio is a precise marker of cholesterol homeostasis, and can be used to predict the 
risk of cardiovascular events24. Nicholls et al. showed that an LDL-C/HDL-C ratio > 2.0 was associated 
with plaque progression (despite statin usage), whereas a ratio < 1.5 was significantly associated with 
plaque regression25. Many studies have indicated that cholesterol homeostasis is a major mechanism for 
Sex Men Women
Genotype (N) AA (542) AT (386) TT (67) p* AT + TT
p** 
(vs. 




Age (years) 55.3 ± 8.9 55.7 ± 8.8 56.5 ± 8.3 0.537 55.9 ± 8.7 0.371 55.1 ± 8.5 54.5 ± 8.4 54.0 ± 8.9 0.501 54.4 ± 8.5 0.289
BMI (kg/m2) 23.6 ± 2.9 24.0 ± 3.2 23.7 ± 2.9 0.161 24.0 ± 3.2 0.086 22.9 ± 3.3 22.8 ± 3.3 23.1 ± 3.4 0.844 22.9 ± 3.3 0.850
Triglycerides 




204.0 ± 30.9 203.9 ± 31.8 209.1 ± 33.4 0.438 204.7 ± 32.1 0.741 218.7 ± 35.5 214.8 ± 35.7 214.2 ± 32.9 0.258 214.7 ± 35.2 0.101
LDL-C  
(mg/dL) 121.0 ± 29.2 119.8 ± 30.2 122.1 ± 31.2 0.769 120.2 ± 30.3 0.662 130.2 ± 33.4 129.2 ± 34.5 125.7 ± 32.2 0.599 128.6 ± 34.1 0.501
HDL-C  
(mg/dL) 59.3 ± 15.7 59.0 ± 15.8 64.0 ± 14.3 0.049 59.7 ± 15.7 0.662 69.5 ± 15.8 68.0 ± 14.5 69.0 ± 14.3 0.403 68.2 ± 14.4 0.212
LDL-C/
HDL-C 2.19 ± 0.79 2.17 ± 0.78 2.00 ± 0.70 0.198 2.15 ± 0.77 0.417 1.99 ± 0.78 2.01 ± 0.78 1.93 ± 0.72 0.721 2.00 ± 0.77 0.964
Uric acid  
(mg/dL) 6.13 ± 1.18 5.94 ± 1.14 5.83 ± 1.26 0.016 5.92 ± 1.16 0.005 4.53 ± 0.98 4.31 ± 0.97 4.23 ± 1.04 0.002 4.30 ± 0.98 0.001
Folic acid  
(ng/mL) 8.44 ± 2.16 8.79 ± 2.39 9.05 ± 1.95 0.054 8.82 ± 2.34 0.021 9.78 ± 3.24 9.76 ± 3.37 9.53 ± 2.78 0.888 9.72 ± 3.28 0.838
Homocysteine 
(nmol/mL)** 9.53 ± 3.92 9.23 ± 2.95 8.63 ± 1.79 0.217 9.16 ± 2.83 0.156 7.19 ± 2.16 7.50 ± 2.98 7.86 ± 2.29 0.142 7.56 ± 2.88 0.076
Energy intake 
(kcal/day) 1,938 ± 350 1,921 ± 381 1,908 ± 308 0.687 1,919 ± 371 0.413 1,553 ± 253 1,543 ± 251 1,530 ± 241 0.740 1,541 ± 249 0.494
Protein intake 
(g/day) 56.1 ± 11.2 55.5 ± 11.4 54.4 ± 10.1 0.407 55.3 ± 11.2 0.272 51.4 ± 10.2 51.5 ± 10.9 50.4 ± 11.3 0.748 51.3 ± 11.0 0.884
Fat intake  
(g/day) 41.8 ± 10.8 41.6 ± 9.94 42.3 ± 11.1 0.881 41.7 ± 10.1 0.891 44.3 ± 11.1 45.0 ± 12.1 45.9 ± 13.9 0.490 45.1 ± 12.4 0.290
Carbohydrate 
intake (g/day) 282.4 ± 69.7 274.8 ± 72.9 269.6 ± 57.6 0.152 274.1 ± 70.9 0.063 216.8 ± 44.8 216.7 ± 45.1 212.2 ± 48.6 0.728 216.0 ± 45.7 0.777
METs (h/day) 14.8 ± 13.7 14.5 ± 14.9 15.3 ± 12.3 0.899 14.6 ± 14.5 0.844 14.6 ± 13.2 15.3 ± 14.4 16.0 ± 13.9 0.596 15.5 ± 14.3 0.342
Table 3.  The distribution of participants, according to sex, for rs1179086. Data are presented as 
means ± standard deviation; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, 
high-density lipoprotein cholesterol; METs, metabolic equivalents. Genotype differences were analysed 
using one-way analysis of variance*, or the t-test**. *Men (TT = 412, TC = 294, CC = 45) Women (TT = 335, 
TC = 237, CC = 48). **Men (TT = 399, TC = 281, CC = 39) Women (TT = 330, TC = 231, CC = 65).
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suppressing cardiovascular disease. In the present study, we used the LDL-C/HDL-C ratio to evaluate 
cholesterol homeostasis because it is a better predictor of future cardiovascular disease than are single 
lipid parameters (e.g., triglyceride, LDL-C, or HDL-C levels)14. However, we did not find a correlation 
between uric acid levels and cholesterol homeostasis for minor alleles in rs1165196 and rs3757131 (data 
not shown). These results suggest that the minor alleles in rs1165196 and rs3757131 had independent 
effects on uric acid levels and cholesterol homeostasis.
Various cardiovascular disease risk factors are reported to be related to homocysteine levels, includ-
ing total cholesterol, other lipids, smoking, and the presence or absence of hypertension and diabetes 
mellitus. However, adjusting for these risk factors only weakly attenuates the strong relationship between 
homocysteine levels and mortality due to cardiovascular causes5. In addition, homocysteine levels are 
higher in patients with gout than in healthy controls, and uric acid levels are known to be correlated 
with homocysteine levels22. In contrast, hyperhomocysteinaemia is not correlated with uric acid levels 
in patients with gout, although there is an inverse association between homocysteine levels and renal 
function26. These reports indicate that hyperhomocysteinaemia, which may be related to uric acid levels 
and cardiovascular mortality, is clearly a cardiovascular risk factor, although the precise relationship 
remains unknown.
Interestingly, an association between hyperlipidaemia and hyperhomocysteinaemia has been sug-
gested. In an animal model, hyperhomocysteinaemia inhibited reverse cholesterol transport by reducing 
circulating HDL levels, via inhibition of apoA-I protein synthesis, and enhanced HDL-C clearance27. 
Therefore, the liver may be a major organ involved in regulating homocysteine and cholesterol homeo-
stasis28. These studies suggest that the interactions between homocysteine and HDL metabolism may be 
clinically important. Based on our findings, the rs1165196 and rs3757131 polymorphisms may be suit-
able biomarkers for cardiovascular disease risk factors, although their direct effect(s) on the metabolic 
pathway remains unknown.
Sex Men Women
Genotype (N) CC (703) CT (264) TT (28) p* CT+ TT
p** (vs. 




Age (years) 55.5 ± 8.8 55.4 ± 8.9 58.0 ± 7.9 0.342 55.7 ± 8.8 0.808 54.7 ± 8.7 54.9 ± 8.0 57.5 ± 7.7 0.293 55.1 ± 8.0 0.496
BMI (kg/m2) 23.7 ± 3.0 24.1 ± 3.2 23.6 ± 2.6 0.155 24.0 ± 3.1 0.073 22.9 ± 3.3 22.7 ± 3.2 23.3 ± 4.0 0.630 22.8 ± 3.3 0.570
Triglycerides 




203.9 ± 31.4 204.6 ± 31.4 212.2 ± 32.8 0.391 205.3 ± 31.6 0.536 217.8 ± 35.1 213.8 ± 37.0 220.7 ± 27.7 0.310 214.5 ± 36.2 0.219
LDL-C  
(mg/dL) 121.0 ± 29.8 119.3 ± 29.3 122.7 ± 30.6 0.673 119.6 ± 29.4 0.501 129.9 ± 33.2 128.0 ± 35.9 131.1 ± 28.6 0.749 128.3 ± 35.2 0.530
HDL-C  
(mg/dL) 58.7 ± 15.4 60.8 ± 16.3 67.0 ± 14.2 0.007 61.4 ± 16.2 0.014 69.2 ± 15.4 67.8 ± 14.8 70.7 ± 12.7 0.449 68.1 ± 14.6 0.362
LDL-C/
HDL-C 2.20 ± 0.79 2.10 ± 0.76 1.94 ± 0.73 0.058 2.09 ± 0.76 0.032 2.00 ± 0.77 2.00 ± 0.80 1.93 ± 0.62 0.919 1.99 ± 0.79 0.962
Uric acid  
(mg/dL) 6.10 ± 1.15 5.86 ± 1.21 5.95 ± 1.42 0.015 5.87 ± 1.23 0.004 4.48 ± 1.00 4.29 ± 0.92 4.19 ± 1.19 0.029 4.28 ± 0.95 0.009
Folic acid  
(ng/mL) 8.43 ± 2.12 9.00 ± 2.52 9.72 ± 1.85 0.001 9.05 ± 2.48 < 0.001 9.70 ± 3.08 9.88 ± 3.74 9.71 ± 2.86 0.830 9.86 ± 3.65 0.572
Homocysteine 
(nmol/mL)** 9.67 ± 3.84 8.63 ± 2.29 8.60 ± 1.60 0.001 8.63 ± 2.25 < 0.001 7.38 ± 2.73 7.34 ± 1.92 7.18 ± 1.93 0.940 7.32 ± 1.91 0.803
Energy intake 
(kcal/day) 1,928 ± 355 1,934 ± 379 1,923 ± 294 0.973 1,933 ± 372 0.854 1,546 ± 247 1,550 ± 260 1,553 ± 267 0.979 1,550 ± 260 0.843
Protein intake 
(g/day) 56.0 ± 11.4 55.2 ± 11.0 55.0 ± 9.86 0.586 55.2 ± 10.9 0.303 51.3 ± 10.5 51.4 ± 10.4 50.5 ± 12.3 0.918 51.3 ± 10.6 0.957
Fat intake  
(g/day) 41.8 ± 10.8 41.6 ± 9.81 42.6 ± 8.92 0.891 41.7 ± 9.71 0.918 44.5 ± 11.7 45.0 ± 11.7 46.0 ± 11.6 0.720 45.1 ± 11.7 0.483
Carbohydrate 
intake (g/day) 279.2 ± 70.6 278.2 ± 70.8 268.1 ± 58.8 0.711 277.2 ± 69.7 0.683 216.1 ± 43.7 217.9 ± 47.9 212.3 ± 56.8 0.794 217.3 ± 48.8 0.718
METs (h/day) 14.9 ± 14.2 14.2 ± 14.1 13.1 ± 8.82 0.649 14.1 ± 13.6 0.396 14.9 ± 13.5 15.4 ± 14.4 12.8 ± 11.5 0.669 15.1 ± 14.1 0.840
Table 4.  The distribution of the participants, according to sex, for rs3757131. Data are presented as 
means ± standard deviation; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, 
high-density lipoprotein cholesterol; METs, metabolic equivalents. Genotype differences were analysed 
using one-way analysis of variance*, or the t-test**. *Men (TT = 530, TC = 204, CC = 17) Women (TT = 435, 
TC = 165, CC = 20). **Men (TT = 507, TC = 198, CC = 14) Women (TT = 427, TC = 160, CC = 19).
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Plasma homocysteine concentrations are typically considered to be inversely related to folic acid levels 
(a cofactor or substrate for enzymes involved in homocysteine metabolism). Similarly, a previous study 
reported that homocysteine levels in elderly Japanese individuals are inversely related to folic acid lev-
els29. Furthermore, another study reported that folic acid supplementation lowered homocysteine levels, 
although the change in lipid metabolism was not significant at the end of the treatment period28,30. 
Nevertheless, the preventative effects of folic acid supplementation on cardiovascular disease cannot be 
excluded31. In the present study, high homocysteine and low folic acid levels were associated with the 
major homozygous alleles in rs1165196 and rs3757131. However, adjusting for folic acid weakly attenu-
ated the relationship between hyperhomocysteinaemia and the SLC17A1 polymorphisms. Nevertheless, 
the odds of hyperhomocysteinaemia were significantly different for rs1165196 and rs3757131, even after 
adjusting for folic acid levels. Therefore, SLC17A1 polymorphisms appear to independently affect low 
homocysteine levels.
To the best of our knowledge, the present study was the first to explore the association between 
rs1165196 and rs3757131 genotypes and cardiovascular risk factors, altered cholesterol homeostasis, 
and homocysteine levels in Japanese men. However, in women, statistically significant differences in 
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Table 5.  Associations between the SLC17A1 gene variants and the LDL-C/HDL-C ratio. SNP, single 
nucleotide polymorphism; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein 
cholesterol; OR, odds ratio; CI, confidence interval. †Adjusted for age, body mass index, research area, 
alcohol consumption, smoking habits. ‡Adjusted for age, body mass index, research area, METs, daily energy 
and nutritional intake (protein, fat, carbohydrate), and alcohol and smoking habits.
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differences in the regulation of uric acid levels have been reported in both humans and animals32. In the 
Framingham Heart Study, the association between uric acid levels and mortality risk in men was not 
significant in the univariate analysis, and the association in women was not significant after adjusting 
for diuretic use, blood pressure, and total cholesterol levels33. Therefore, the specific physiological char-
acteristics of women may be related to the sex-related differences in SNP genotypes that were observed 
to be associated with uric acid levels, although the underlying mechanism has yet to be elucidated. 
Furthermore, alcohol consumption, physical activity, and daily energy and nutrition intake did not affect 
the associations in either men or women. Therefore, identification of the pathogenic genetic factor(s) for 
cardiovascular disease remains critically important.
The limitations of our study include its cross-sectional design and the relatively small number of 
participants. Although a study with a low statistical power has a reduced likelihood of detecting a true 
effect, case-control studies with small sample sizes are still widely used, and can be used to assess pre-
viously identified candidate regions and more precisely determine target selections. In addition, we 
only assessed Japanese participants in the present study, and further studies in other ethnic groups are 
needed to validate our findings. Therefore, large, prospective trials involving patients from multiple eth-
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Table 6.  Associations between the SLC17A1 gene variants and hyperhomocysteinaemia. SNP, single 
nucleotide polymorphism; OR, odds ratio; CI, confidence interval. †Adjusted for age, body mass index, 
research area, alcohol consumption, smoking habits. ‡Adjusted for age, body mass index, research area, folic 
acid, alcohol consumption, smoking habits.
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Conclusion
In conclusion, our results indicate that the rs1165196 and rs3757131 polymorphisms, expressed in the 
liver, confer dominant negative effects on LDL-C/HDL-C ratios and hyperhomocysteinaemia in Japanese 
men. Although the exact biological mechanism for this association remains unknown, our findings 
provide credible evidence that the rs1165196 and rs3757131 polymorphisms may be associated with a 
decreased risk of cardiovascular disease. This risk reduction may be due to their important role in main-
taining cholesterol homeostasis and preventing hyperhomocysteinaemia through altered liver function. 
However, further studies are needed to interpret the effects of SLC17A1 polymorphisms on cardiovas-
cular disease.
Methods
Study participants. In the present study, we evaluated participant data collected during the Japan 
Multi-Institutional Collaborative Cohort (J-MICC) Study. That cohort study evaluated the general 
Japanese population in 10 research areas, using genetic and clinical data to detect and confirm gene-en-
vironment interactions related to lifestyle-associated diseases34. The study participants were 35–69 years 
old, and were enrolled after responding to study announcements in their specific research areas, attend-
ing health check-up examinations that were commissioned by their local governments, visiting local 
health check-up centres, or visiting a cancer hospital. A total of 4490 participants were selected, with 
approximately 500–600 participants from each research area, except for two areas in which fewer par-
ticipants were recruited35.
Among these 4490 participants, 2035 were excluded because they had consumed a meal < 6 h before 
having their blood drawn, 228 because they were receiving cholesterol-lowering medication, 24 due to 
high triglyceride levels (≥ 400 mg/dL), 338 due to insufficient laboratory data, and 23 individuals were 
excluded due to the absence of other data. After these exclusions, 1842 individuals (995 men and 847 
women) were eligible for analyses. Folic acid (751 men and 620 women) and homocysteine (719 men 
and 606 women) levels limited the number of participants.
All participants provided written informed consent for the J-MICC Study, and the main study pro-
tocol of the J-MICC Study was approved by Ethics Committee at Nagoya University School of Medicine 
(Approval number 253 and 939). Since actual studies are slightly different from the main J-MICC Study 
protocol, all procedures involved in this study were performed in accordance with the institutional ethi-
cal committees (Chiba Cancer Center, Nagoya University, Nagoya City University, Aichi Cancer Center, 
Shiga University of Medical Science, Kyoto Prefectural University of Medicine, Tokushima University, 
Kyushu University, Saga University, and Kagoshima University).
Blood biochemistry, lifestyle, and nutritional data. In the present study, we evaluated lifestyle 
and medical information obtained through self-administered questionnaires (alcohol consumption sta-
tus [0, 0.1–22.9, 23.0–45.9, or ≥ 46.0 g ethanol/day], smoking habits, current medications, and exercise). 
In addition, blood chemistry data (serum levels of triglycerides, total cholesterol, HDL-C, uric acid, 
LDL-C [calculated using the Friedewald formula36, and plasma levels of homocysteine and folic acid) and 
anthropometric data were obtained from health check-ups performed in the research areas. Each blood 
sample was centrifuged and the plasma was separated and stored at –80 °C until analysis. Serum samples 
were measured by laboratories in each research area. Plasma folic acid concentrations were measured 
using a chemiluminescent enzyme immunoassay, and plasma homocysteine concentrations were meas-
ured using high-performance liquid chromatography by a contract laboratory (SRL, Tokyo, Japan).
For the dietary assessment, a validated food-frequency questionnaire was used to evaluate the intake 
frequency of 47 foods and beverages over the preceding year, and the total daily energy (kcal), protein 
(g), fat (g), and carbohydrate (g) intakes were calculated37–40. Physical activity was assessed as METs for 
daily and leisure activities, as previously reported41. In brief, METs-hours per day (METs·h/day) of daily 
activity were estimated for heavy physical work and walking. For leisure activities, METs·h/day were 
estimated by multiplying the reported daily time spent in each activity by the relevant MET intensity.
Genotyping SLC17A1 polymorphisms. Our previous study described the details of the genetic 
analysis35. Briefly, genomic DNA was extracted from the buffy coat fraction of the participant’s blood 
sample, using a BioRobot M48 Workstation (QIAGEN Group, Tokyo, Japan). The SLC17A1 polymor-
phisms (rs1165196, rs1179086, and rs3757131) were genotyped using a multiplex polymerase chain 
reaction-based Invader assay (Third Wave Technologies, Madison, WI, USA) at the RIKEN Laboratory 
for Genotyping Development, Center for Genomic Medicine (Yokohama, Japan)42. The rs1165196 pol-
ymorphism is located at exon 7, where a conversion from thymine to cytosine at nucleotide 806 results 
in the substitution of threonine for isoleucine. The rs1179086 and rs3757131 polymorphisms are located 
at intron 1218.
Statistical analyses. Inter-group comparisons were performed using Student’s unpaired t-tests for 
continuous variables and chi-square tests for categorical variables (alcohol consumption in current 
drinkers, smokers, and allele independence [Hardy-Weinberg equilibrium]). Differences in quantitative 
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data, between the genotypes, were evaluated using one-way analysis of variance. All data were expressed 
as means ± standard deviation, or as indicated, and the coefficients of variation (CVs) for each param-
eter were calculated. ORs, 95% CIs, and p-values were calculated using logistic regression analyses; the 
LDL-C/HDL-C ratio (> 2.0) was defined as the dependent variable, and participant age, sex, BMI (kg/
m2), research area, METs, daily energy and nutritional intake (protein, fat, and carbohydrate), and  alcohol 
consumption and smoking habits, were included as independent variables. In the general Japanese popu-
lation, a plasma homocysteine concentration of > 10.0 nmol/mL is defined as hyperhomocysteinaemia29, 
and this cut-off value was used for our analyses. We performed logistic regression analyses with the 
homocysteine level defined as the dependent variable, and patient age, sex, BMI, research area, folic acid 
level, and alcohol consumption and smoking habits were included as independent variables. All statistical 
tests were two-sided, and differences with a p-value of < 0.05 were considered statistically significant. 
SPSS software (version 18.0, SPSS, Japan, Inc.) was used for all statistical analyses.
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